In 2012, researchers identified Y211 phosphorylation of PCNA as a marker for prostate cancer and developed a synthetic Y211F peptide to inhibit this modification, which enhanced cancer cell death (Zhao et al., 2011). This evidence concerns the gene PCNA and cancer.